Qingdao Vland Biotech INC. (603739.SS)

CNY 13.0

(0.54%)

Market Cap (In CNY)

3.28 Billion

Revenue (In CNY)

1.18 Billion

Net Income (In CNY)

80.7 Million

Avg. Volume

8.24 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.7-22.35
PE
-
EPS
-
Beta Value
0.465
ISIN
CNE100003GX8
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gang Chen
Employee Count
-
Website
https://www.vlandgroup.com
Ipo Date
2019-01-29
Details
Qingdao Vland Biotech INC. engages in the research and development of enzymes, probiotics, and animal vaccines and health products. It offers animal feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated poultry, and swine vaccines, as well as antibodies; poultry drugs comprising anti-parastic, antiviral, and nutritional drugs, as well as disinfectants; and traditional Chinese veterinary medicines for scale and avian breeding, livestock, and laying hens. It serves agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel, environmental protection, and other industries. The company was incorporated in 2005 and is headquartered in Qingdao, China. Qingdao Vland Biotech INC. operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.